化疗与贝伐珠单抗联合治疗晚期非小细胞肺癌的效果与安全性分析  

Analysis on the Efficacy and Safety of Chemotherapy Combined with Bevacizumab in the Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：郭丽芳[1] 周建华[1] GUO Lifang;ZHOU Jianhua(Department of Pharmacy,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450003,China)

机构地区：[1]郑州大学第二附属医院药学部,河南郑州450003

出　　处：《临床医学工程》2024年第2期201-202,共2页Clinical Medicine & Engineering

摘　　要：目的 分析化疗联合贝伐珠单抗治疗晚期非小细胞肺癌(NSCLC)的效果和安全性。方法 90例晚期NSCLC患者随机分为两组,对照组给予常规化疗,观察组在对照组基础上给予贝伐珠单抗治疗,比较两组的治疗效果与安全性。结果 治疗后,观察组的治疗总有效率高于对照组,血清CEA、 CA125、 VEGF水平均低于对照组(P <0.05)。两组的各项不良反应发生率比较,差异均无统计学意义(P>0.05)。结论 化疗联合贝伐珠单抗联合治疗晚期NSCLC的效果显著,安全性高。Objective To analyze the effect and safety of chemotherapy combined with bevacizumab in the treatment of advanced non-small cell lung cancer(NSCLC).Methods 90 patients with advanced NSCLC were randomly divided into two groups.The control group was given conventional chemotherapy,and the observation group was treated with bevacizumab on the basis of the control group.The treatment effect and safety were compared between the two groups.Results After treatment,the total effective rate of treatment in the observation group was higher than that in the control group,and the levels of serum CEA,CA125 and VEGF were lower than those in the control group(P <0.05).No statistical difference was found in the incidences of adverse reactions between the two groups(P >0.05).Conclusions Chemotherapy combined with bevacizumab in the treatment of advanced NSCLC has significant effect and high safety.

关 键 词：晚期非小细胞肺癌 化疗 贝伐珠单抗 疗效 安全性 

分 类 号：R734.2[医药卫生—肿瘤]